Point72 Asset Management, L.P. - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 152 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is 0.31 and the average weighting 0.0%.

Quarter-by-quarter ownership
Point72 Asset Management, L.P. ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q4 2022$2,057,131
-90.5%
166,300
-89.3%
0.01%
-92.0%
Q3 2022$21,751,000
+1137.3%
1,559,183
+1124.8%
0.09%
+1142.9%
Q2 2022$1,758,000
+41.2%
127,300
+66.4%
0.01%
+40.0%
Q1 2022$1,245,000
-85.1%
76,500
-85.1%
0.01%
-84.8%
Q4 2021$8,376,000
-19.3%
514,200
-26.4%
0.03%
-28.3%
Q3 2021$10,376,000
-85.7%
698,700
+7.8%
0.05%
-86.0%
Q1 2019$72,516,000
+655.8%
648,278
+581.0%
0.33%
+615.2%
Q4 2018$9,595,000
+1360.4%
95,200
+1730.8%
0.05%
+1433.3%
Q3 2018$657,000
-96.2%
5,200
-98.2%
0.00%
-95.8%
Q1 2018$17,342,000
+979.2%
281,900
+925.1%
0.07%
+928.6%
Q4 2017$1,607,000
-51.8%
27,500
-52.2%
0.01%
-53.3%
Q3 2017$3,337,000
-90.3%
57,500
-79.9%
0.02%
-92.3%
Q2 2017$34,578,000
+38.6%
285,600
+29.5%
0.19%
+39.6%
Q1 2017$24,950,000
+17.7%
220,600
+13.1%
0.14%
-6.1%
Q4 2016$21,198,000
+1502.3%
195,100
+1794.2%
0.15%
+1380.0%
Q1 2016$1,323,000
-96.5%
10,300
-92.2%
0.01%
-96.1%
Q1 2015$37,311,000
-20.3%
132,300
-55.9%
0.25%
-22.8%
Q4 2014$46,831,000
+430.4%
300,200
+704.8%
0.33%
+398.5%
Q3 2014$8,829,000
+40.8%
37,300
+40.8%
0.07%
+65.0%
Q2 2014$6,271,00026,5000.04%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q2 2022
NameSharesValueWeighting ↓
Samsara BioCapital, LLC 640,688$9,514,0001.49%
CM Management, LLC 45,000$668,0000.50%
EULAV Asset Management 660,000$9,801,0000.26%
DLD Asset Management, LP 225,200$3,346,0000.24%
Virtus ETF Advisers LLC 21,387$318,0000.14%
GSA CAPITAL PARTNERS LLP 79,145$1,175,0000.12%
Hennion & Walsh Asset Management, Inc. 136,720$2,030,0000.11%
ALTRINSIC GLOBAL ADVISORS LLC 168,800$2,507,0000.08%
Inspire Investing, LLC 31,868$473,0000.06%
DUALITY ADVISERS, LP 51,196$760,0000.06%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders